Anti-VEGF Eye Injections tied to minor Increase in Stroke Risk, suggests research
A recent nationwide case-control study published in Acta Ophthalmologica found that intravitreal injections of anti-VEGF agents for neovascular age-related macular degeneration (nAMD) were associated with a small yet statistically significant increase in the risk of stroke or transient ischemic attack (TIA), especially within the first 60 days following treatment. Analyzing records for over 33,000 nAMD patients between 2007 and 2019, researchers identified 1,693 who experienced a stroke, with 936 occurring within 90 days after receiving anti-VEGF injections. Compared to non-users, patients had a 27% increased relative risk (RR = 1.27; 95% CI 1.22–1.33) of stroke or TIA in that window. The highest risks were observed within 30 days (RR = 1.36) and 31–60 days (RR = 1.40) post-injection, while stroke risk declined significantly between 61 and 90 days (RR = 0.58) PubMed.
These findings suggest a modest systemic impact from intravitreal anti-VEGF therapy, particularly with agents such as aflibercept and bevacizumab, which appeared to elevate stroke risk more than ranibizumab—though data specifics weren’t disclosed in the public summary Wiley Online Library. The increased risk seems to wane after two months, potentially reflecting partial systemic absorption or the physiological effects of VEGF suppression on blood vessels.
Though the increased risk is small, clinicians should weigh benefits and risks, especially in patients with known vascular vulnerabilities. For most individuals with nAMD, anti-VEGF treatment remains a safe, effective standard therapy. Still, these results underline the importance of careful monitoring following injections, particularly in the early post-treatment period.
Keywords: anti-VEGF injections, stroke risk, transient ischemic attack, neovascular AMD, intravitreal therapy, aflibercept, bevacizumab, ranibizumab, vascular safety, Acta Ophthalmologica
